COVID-19 vaccine

2022 - 12 - 21

Post cover — Image courtesy of "FiercePharma"

What's next for the COVID-19 vaccine game and its star players? (FiercePharma)

The respiratory syncytial virus (RSV) race features key players such as Pfizer, GSK, Sanofi and AstraZeneca. The market is said to be worth $10.5 billion over ...

At the time, Porges expected GSK to pick up $2.9 billion of that total revenue by 2030, with Pfizer taking $2.1 billion, J&J collecting $1.7 billion and Sanofi snagging $1.2 billion. The respiratory syncytial virus (RSV) race features key players such as Pfizer, GSK, Sanofi and AstraZeneca. She predicted the higher price would likely kick in during the first quarter of 2023. market could be as low as one-third the size of the flu market,” Brown wrote this fall, citing less enthusiasm for booster shots. But the team noted noted the higher price could discourage vaccination among those who are uninsured or underinsured. The danger really is to draw the wrong conclusions from some number on an order book. [said](https://www.fiercepharma.com/pharma/biontech-after-surprising-third-quarter-and-strong-booster-sales-adjusts-vaccine-revenue) at the time. GSK It’s a story that doesn’t need recapping, but the height of the action seems to be winding down. Next year, we'll see more changes that'll force the top players to pivot. Lee Brown, global sector lead for healthcare at Third Bridge Group, [slashed](https://www.fiercepharma.com/pharma/moderna-slashes-covid-vaccine-sales-projection-after-quarter-pain-points) its annual sales projection for its vaccine from $21 billion to the $18 billion to $19 billion range.

MHRA authorizes the COVID-19 vaccine developed by Sanofi (News-Medical.net)

VidPrevtyn Beta, the COVID-19 vaccine developed by Sanofi, has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).

The authorization is for the use of this vaccine in those aged 18 and over, as a heterologous booster dose, given as a single injection. This means that those who received a different vaccine (mRNA or viral-vectored) as a primary course, can receive this vaccine as a booster. The clinical evidence for this authorization is based on data from about 800 individuals previously immunized with an mRNA or viral-vectored vaccine.

PHASE Scientific Americas and Dr. B Partner to Make it Easier than ... (StreetInsider.com)

After Testing Positive with PHASE's INDICAID® Rapid Antigen At-Home Test, Patients Can Now Conveniently Access Dr. B's Low-Cost Telehealth Service for ...

Dr. With Dr. § 360bbb-3(b)(1) unless the authorization is terminated or revoked sooner. We are committed to providing patients and healthcare providers with innovative diagnostic and data tools that will assist them in understanding their health and making better health decisions. “Experts have warned that with new COVID-19 subvariants, healthy adults are more likely to be infected even after vaccination or a previous infection,” said Cyrus Massoumi, Founder and CEO of Dr. “We strongly believe in the Test-to -Treat concept and are proud to be able to offer this extended capability to our customers. B offers consultations for Paxlovid and Molnupiravir (Lagevrio) — the two at-home oral COVID-19 antivirals authorized for use by the The INDICAID® COVID-19 Antigen Rapid At-Home Test eliminates the need to wait for appointments and reduces the time it takes to receive results, so patients who test positive can more quickly access treatments from services like Dr. COVID-19 cases and related hospitalizations are ticking up in a number of U.S. The INDICAID Test-to-Treat program enables patients who test positive for COVID-19 with a rapid antigen test to access treatment without delay. B](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhidrb.com%2F&esheet=53102399&newsitemid=20221221005035&lan=en-US&anchor=Dr.+B&index=2&md5=cf553475cfcbc271319f48879b9f9264), the only telehealth service that makes healthcare services available regardless of a patient’s ability to pay. [PHASE Scientific Americas](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.phasescientificamericas.com%2F&esheet=53102399&newsitemid=20221221005035&lan=en-US&anchor=PHASE+Scientific+Americas&index=1&md5=36dff3f9777ee3995221ceb243826479), a health diagnostics innovator and maker of INDICAID® Rapid Antigen Tests, announces a new partnership with [Dr.

HHS & ACL Slot $125M to Address Flu, COVID-19 Vaccine Access ... (PatientEngagementHIT.com)

The funding will focus on leveraging partnerships across the aging and disability networks to overcome flu and COVID-19 vaccine access barriers for older ...

“Staying up-to-date on vaccinations is the most important thing we all can do to protect ourselves from serious illness due to COVID-19 and flu as we head into winter, and it’s particularly crucial for older adults and people with disabilities, who face the greatest risks,” Alison Barkoff, ACL acting administrator and assistant secretary for aging, said in a press release. Partnerships are a central element of each grant, ACL stated. The funding will focus on leveraging partnerships across the aging and disability networks to overcome flu and COVID-19 vaccine access barriers for older adults and people with disabilities.

Progress with COVID-19 vaccination among respondents to the ... (World Bank Group)

The Uganda Bureau of Statistics (UBOS) continues data collection for the Uganda High-Frequency Phone Survey (UHFPS). The survey was initially used to track ...

Second, an upward bias in self-reported vaccination rates may be related to the non-random nature of respondents to the phone survey as many of them are heads of households who are older, more educated, and more resourceful than the general adult population. Interestingly, reported readiness to be vaccinated has a significant positive impact on the probability of having full vaccination status, but not on the probability of having at least one shot as shown in figure 2. Agreeing to be vaccinated reported in October 2020 is associated with an increased probability of being fully vaccinated by August 2022 by 17%, while association with probability of having at least one shot is not significantly different from zero. On average, about seven people out of 10 were vaccinated in the community according to respondents. The youngest respondents (aged 15-24), those without formal education, and respondents from the poorest pre-COVID-19 consumption quintile had the lowest shares of fully vaccinated respondents. The Uganda Bureau of Statistics (UBOS) continues data collection for the Uganda High-Frequency Phone Survey (UHFPS).

Covid-19 Nasal Vaccine: 'नेजल वैक्सीन को मिली मंजूरी, अब इंजेक्शन की ... (ABP News)

Mansukh Mandaviya ने राज्यसभा में बताया कि देश भर के बड़े अस्पतालों में ऑक्सीजन प्लांट लगाए गए ...

केंद्रीय स्वास्थ्य मंत्री ने कहा कि हम वैश्विक कोविड स्थिति पर नजर रख रहे हैं और उसी के अनुसार कदम उठा रहे हैं. वैक्सीन को अमेरिका के मिसूरी के सेंट लुइस स्थित वॉशिंगटन विश्वविद्यालय के साथ साझेदारी में विकसित किया गया है. भारत बायोटेक के बयान के मुताबिक, iNCOVACC आसान भंडारण और वितरण के लिए दो से आठ डिग्री सेल्सियस पर रखी जा सकती है.